Xconomy

JUNE 10, 2016

—Meanwhile, check out reports here , here , and here for some of the other headlines coming out of ASCO, including progress made in cancer immunotherapy, the ups and downs from various presenting companies, and a visit from Vice President Joe Biden. Ed Silverman at STAT reported the analyst note first.

Incubator 67

Incubator Thousand Oaks Screening Pricing 67

Xconomy

SEPTEMBER 30, 2016

Who will break free of the pack of companies developing drugs meant to prevent migraines? —Amgen (NASDAQ: AMGN ), of Thousand Oaks, CA, and partner Novartis released positive results from the first Phase 3 trial of erenumab , one of a group of drugs being developed to prevent migraines , not just lessen their impact when they happen.

Avalon 40

Avalon Thousand Oaks Study Startup 40

Xconomy

AUGUST 26, 2016

—Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, said that the FDA rejected its drug etelcalcetide (Parasbiv) , a treatment for patients with an excess of damaging hormone release because of chronic kidney disease. Alex Lash contributed to this report. Morgan party. Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 40

Pricing Thousand Oaks Startup Research 40

Xconomy

JULY 22, 2016

—Celgene (NASDAQ: CELG ), of Summit, NJ, inked its latest immuno-oncology deal, forming a wide-ranging alliance with Cambridge-based Jounce Therapeutics to develop a group of cancer drugs. Also in Cambridge, Oncorus debuted with a $57 million round and a plan to develop next-gen oncolytic viruses, a type of cancer immunotherapy tool.

Startup 40

Startup San Diego News Thousand Oaks 40

Xconomy

AUGUST 5, 2016

Instead, Holmes promoted a new system, MiniLab , in development. The Wall Street Journal reported that Cambridge, MA-based Biogen (NASDAQ: BIIB ) has drawn interest from the likes of Merck (NYSE: MRK ) and Allergan (NYSE: AGN ) as a possible takeover target. Bigelow contributed to this report. Shares fell about 5 percent.

News 40

News Thousand Oaks Pricing Report 40